NeuroTheranostics, Inc. has established its initial team in executive management and scientific/clinical advisory board. The clinical and scientific team members have collaborated with the founder for a period ranging from 10-25 years while the management team has provided advice since company inception.

 

Dr. John Anagli: Founder/CEO/CSO. John has over 30 years of therapeutics development and twelve years of biomarker-related product development leadership, as well as medical, pharmaceutical, biotechnology and academic research experience both in Europe and the US. He is an inventor of several novel compounds and methods for treating brain damage following ischemia and trauma, as well as novel blood-based and molecular imaging biomarkers.

 

Dr. Patrick Leconte: Treasurer. Patrick has over two decades of experience in business management and organizational development. He has helped health-related companies bridge the gap from conceptualization to commercialization. His expertise includes private funding, staff development and organizational culture.

 

J. David Allen: Business Development. David has over 35 years of executive leadership experience. He has participated in multiple technology startups, large-scale turnarounds, and large financial exits and post-merger restructurings.

 

Jacob Keli: Finance. Jacob has over 30 years of extensive corporate and public service executive leadership experience and knowledge in banking, finance, international trade, organizational development, and management.

 

David and Jacob are currently advisors, and not part of the management team. It is anticipated that David and Jacob will become part of the management team when a major investment agreement is finalized.